Who asks the questions.

Shouldn't that decision belong further along the chain?

A woman in her late forties came to see me recently. She had no symptoms, but both her mother and her aunt had died of pancreatic cancer before seventy. She'd read about imaging that could look at the pancreas, done the reading herself, and arrived asking whether it was reasonable. We talked it through — her family history, her own risk picture, what we would and wouldn't do with unexpected findings. She went ahead with a targeted MRI. It was normal, which was the most likely outcome, and she left with something she'd been carrying for years eased. The scan itself wasn't the point. The conversation around it was.

A colleague later asked me why I hadn't referred her to a secondary provider — a cardiologist, gastroenterologist, or other downstream specialty clinician — before ordering the scan. The question underneath was sharper: shouldn't that kind of decision belong to someone further along the chain?

It's a fair question, and it sits at the centre of a shift happening in medicine that we haven't quite named yet.

An architecture of scarcity.

For most of the last century, medicine worked on an architecture of scarcity. The good diagnostic tools were expensive, specialised, and reached through a referral chain that concentrated interpretation in the hands of secondary providers. The generalist physician's job was to spot when a patient needed more than primary care could offer and pass them along. The secondary provider's job was to decide what tests to do, read the results, and send back a plan. This made sense when coronary imaging needed a team in a cath lab, when an MRI was a tertiary hospital resource, when genetic testing took weeks and cost a fortune. The gatekeeping was how we rationed genuinely scarce things.

That architecture is falling apart, and most of our professional conversation about it is defensive rather than curious.

Coronary CT angiography used to live inside cardiology. It now lives inside radiology, ordered by generalist physicians, read by cardiac radiologists, and folded into preventive workups alongside ApoB, lipoprotein(a), metabolic markers, and family history. Targeted MRI of the pancreas, prostate, or brain was once routed through the relevant secondary specialty. It is now increasingly ordered by generalist and preventive health physicians and reported by subspecialty radiologists. Whole-body MRI used to be a research tool. It's now available to anyone with a few thousand dollars and a browser. Multi-cancer blood tests, self-managed testing, genetic risk scores, at-home hormone panels, microbiome sequencing, polygenic scores — each of these was secondary-provider-mediated a decade ago. Each is now directly available, often without a doctor involved at all.

Doctor-absent diagnostics are not the alternative to gatekeeping. They are the consequence of it.

The usual professional response is to raise concerns. About appropriateness. About incidental findings. About the cascade of further tests that follow unexpected results. About turning healthy people into patients. These concerns aren't wrong. But they're incomplete — and they often function as cover for a narrower concern about professional territory.

Here's what I've come to think is closer to the truth. The question is no longer whether these tests exist in the patient's world. They do. The patient can order them directly. The market has already answered. The only real question left is whether a thoughtful doctor is involved in helping the patient use the information well — or whether they're left reading their own scan report at 2am with a browser tab open.

A future in which doctors aren't involved is genuinely worse than the old model. But doctor-absent diagnostics aren't the alternative to gatekeeping. They are the consequence of it. When medicine insists that only secondary providers may touch these tests, patients who want them simply go around the profession. The direct-to-consumer industry exists because traditional medicine left the space empty. Stepping back into that space means letting go of the idea that access itself is the problem.

What this new landscape asks of doctors isn't less clinical thinking. It's more of it. The work isn't ordering the scan. The work is deciding, for a specific person, whether to order it, which one, when, what to look for, what to do with unexpected findings, and how to pull the result together with everything else we know — their bloods, their family, their life stage, their values. That kind of integration is harder than referring someone onward.

It's also, increasingly, what good preventive medicine actually looks like.

Consumerism is the water medicine has always swum in.

It's worth pausing here to say something honest about the patients we are now meeting. The familiar phrase "more informed patients" undersells what is actually happening. We are living through a biotech age in which science and technology dominate education, in which a generation has grown up with genetics, immunology, molecular biology, and data science as everyday vocabulary. The pandemic accelerated this dramatically — mRNA platforms, viral evolution, population epidemiology, risk modelling, and pharmacovigilance all became dinner-table topics.

The patients walking into our rooms today are often biologically and scientifically literate in ways the profession hasn't fully absorbed. Many are as fluent in the primary literature relevant to their own condition as the clinicians they consult, and in specific niches they know more. This isn't a threat to good medicine. It's a sign of a maturing knowledge economy, and it reshapes what patients reasonably expect from a clinical encounter. They are no longer seeking permission to know. They are seeking a thinking partner to help them act on what they already know.

Which brings me to the second thing worth naming.

"Consumerism in medicine" isn't a modern corruption of some purer earlier practice. It's the water we've always swum in. Patients have always chosen — which GP to enrol with, which hospital to travel further for, which specialist their cousin recommended, which obstetrician or midwife for the birth, which aged care facility for a parent, which private insurance plan, which pharmacy, which brand of paracetamol on the supermarket shelf. Doctors have always chosen too — which colleges to join, which hospital to credential at, which suburb to practise in, which referral networks to cultivate. The consumer choices were just less visible historically — shaped by referral networks, reputation, geography, insurance coverage, and class rather than by websites and price lists. What's changed is how visible the choosing is, not that it happens.

This matters because much of the professional objection to newer models of care takes the form of moral disapproval of consumerism. The implicit claim is that doctors in traditional settings stand outside the market and can moderate the market choices of their patients from a neutral vantage point. That claim doesn't survive much scrutiny. The generalist physician in a bulk-billed or very-low-cost clinic, the secondary provider in a teaching hospital, the preventive health physician in private practice — all of them operate inside market conditions that shape what they offer, how they price it, who they see, and how they're perceived. There's no view from nowhere.

It's also worth being honest that commercial and professional interests aren't a primary-care phenomenon. Secondary care has its own, often deeper, entrenchments. Colleges have historically shaped which investigations belong to which specialty, which procedures can be done by whom, and which referral pathways are considered "appropriate." Private secondary practice, hospital-based imaging, and procedural medicine are substantial commercial enterprises. None of this is a criticism of individual clinicians, most of whom practise with real integrity within the structures they've inherited. It's simply to say that when secondary providers express concern about generalists ordering investigations directly, part of what's happening is clinical and part is structural — and the honest conversation separates the two.

The real question isn't whether to be shaped by the market. It's which market signals to amplify and which to push back against.

Some signals point toward better care. Patients want continuity. They demand the joining up of fragmented care. They are willing to pay for time and attention. They are interested in prevention rather than reaction. These are worth amplifying.

Some signals point toward worse care. Pressure toward shorter appointments. Incentives that reward procedures over thinking. Testing without interpretation. Commercial pressure to prescribe particular drugs or order particular scans. These are worth resisting.

The work of practising with integrity is telling the difference. It isn't pretending to stand outside the market.

The diversification of pathways is a sign of maturity, not a symptom of decay.

What actually separates considered from unconsidered practice in this new landscape isn't the number of tests. It's the quality of thinking that goes into each one. A generalist physician who orders a comprehensive workup after carefully integrating family history, bloods, cardiometabolic picture, and the patient's own goals is doing good medicine. A generalist physician who orders the same tests from a reflexive menu isn't. A generalist physician who refers every moderate-risk patient onward because the guidelines say so may be doing less integration than one who orders the scan themselves. The latter reads it in context, and escalates only when the question genuinely needs a secondary provider.

This isn't an argument for unregulated access. It's an argument for competent decentralisation — the recognition that clinical expertise no longer lives only at the secondary end of the referral chain, and that generalist and preventive health physicians who have done the upstream thinking are legitimate stewards of investigations that were once secondary-only. Secondary providers remain essential when the question genuinely needs their depth of expertise. They aren't essential as routine gatekeepers for investigations a well-trained generalist can handle.

And here is perhaps the deepest point.

The rise of preventive medicine, the booming radiology and pathology sectors, the growth of advanced diagnostics, the emergence of generalist physicians and non-physician providers working at the top of their scope — none of this is a symptom of medicine going wrong. It is a sign of medicine going through the same transformation every maturing sector goes through as a society accumulates resources, knowledge, and technical sophistication. A simple ecosystem has few niches. A mature one has many, and the diversity is a feature rather than a flaw. In entropic terms, the diversification of diagnostic and preventive pathways is what an energy-rich, information-rich, resource-rich health economy looks like. Simpler systems have one default option. Ours today have many. The existence of many paths is how the system becomes resilient, responsive, and capable of meeting patients where they actually are.

The forces driving this shift — increasing life expectancy, a scientifically literate public, more accessible technology, and the limits of standard primary care for an ageing yet proactive population — are structural rather than faddish. Medicine will adapt to them or be routed around by them.

The generalist and preventive health physicians who will do the most good over the next two decades aren't the ones who guard the old architecture most loyally. They're the ones learning to practise thoughtfully inside the new one — bringing rigour, integration, continuity, and judgment to a landscape where the scans and the data are becoming cheap, but the synthesis is not.

The scan is data. The synthesis is medicine.

The scan is data. The synthesis is medicine. The relationship in which the synthesis happens is what patients are actually paying for. And it's the part that can't be automated away.

That's the work worth doing.